Overview
QGEN market data
Price History
QGEN price chart · 1M
- O
- 43.74
- H
- 44.18
- L
- 43.66
- C
- 43.75
- Vol
- 107,687.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $43.74
- Previous Close
- $43.36
- Day High
- $44.18
- Day Low
- $43.66
- 52 Week High
- $45.52
- 52 Week Low
- $32.24
- 7 Day Return
- -2.60%
- 30 Day Return
- +3.61%
- 90 Day Return
- +20.61%
- 1 Year Return
- +31.25%
- Daily Notional Volume
- $4.7M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 22.14 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.94 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.62 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 19.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $32.53 – $57.82 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $8.9B · P/B 2.58 · P/S 4.24.
Company News
QIAGEN Appoints Jonathan M. Pratt CEO, Effective Sept. 1, Succeeding Thierry Bernard; Co. Reiterates Q3, FY26 GuidanceBenzinga · Aug 24, 2026, 1:51 PM
QIAGEN Says FDA Clears QIAstat-Dx BCID GPF Plus AMR Panel For Bloodstream InfectionsBenzinga · Aug 10, 2026, 8:22 PM
Citigroup Maintains Neutral on Qiagen, Raises Price Target to $45Benzinga · Aug 10, 2026, 2:34 PM
Barclays Maintains Equal-Weight on Qiagen, Raises Price Target to $40Benzinga · Aug 7, 2026, 6:53 PM
JP Morgan Maintains Overweight on Qiagen, Raises Price Target to $50Benzinga · Aug 7, 2026, 4:21 PM
Conference Call: Qiagen Q3 Adj EPS expected to be more than $0.62 vs $0.64 Est; Sees Q3 Sales $538.330M-$543.660M vs $552.590M EstBenzinga · Aug 6, 2026, 9:23 PM
Qiagen FY2026 Adj EPS expected to be more than $2.43 vs $2.42 Est; Affirms FY2026 Sales Guidance of $2.111B-$2.132B vs $2.139B EstBenzinga · Aug 5, 2026, 8:20 PM
Qiagen Q2 Adj. EPS $0.62 Beats $0.60 Estimate, Sales $535.000M Beat $527.484M EstimateBenzinga · Aug 5, 2026, 8:12 PM
Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption AccelerateGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Qiagen Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak; Says Qiagen’s FDA-Cleared QIAstat-Dx Gastrointestinal Panel 2 Can Detect Cyclospora Infections In About An Hour As Part Of A 16-Target Gastrointestinal Pathogens MenuBenzinga · Jul 15, 2026, 8:09 PM